News

Biogen to Report Third Quarter 2024 Financial Results October 30, 2024

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™

Biogen Board Appoints Two New Independent Directors

Biogen to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain

Biogen to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates

Biogen Reports Second Quarter 2024 Results